schliessen

Filtern

 

Bibliotheken

Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models

The kinetics of an indium-111 labeled bleomycin complex (111In-BLMC) after rapid intravenous injection in patients with brain tumors was quantified by using compartmental and non-compartmental models. The models were applied to data obtained from 10 glioma, one meningioma, and one adenocarcinoma bra... Full description

Journal Title: Annals of nuclear medicine 1998-12, Vol.12 (6), p.313-321
Main Author: Ryynänen, P M
Other Authors: Savolainen, S E , Aronen, H J , Korppi-Tommola, E T , Huhmar, H M , Kallio, M E , Hiltunen, J V
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Japan
ID: ISSN: 0914-7187
Link: https://www.ncbi.nlm.nih.gov/pubmed/9972368
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_69168876
title: Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models
format: Article
creator:
  • Ryynänen, P M
  • Savolainen, S E
  • Aronen, H J
  • Korppi-Tommola, E T
  • Huhmar, H M
  • Kallio, M E
  • Hiltunen, J V
subjects:
  • Adenocarcinoma - metabolism
  • Adenocarcinoma - secondary
  • Adult
  • Aged
  • Bleomycin - analogs & derivatives
  • Bleomycin - blood
  • Bleomycin - pharmacokinetics
  • Brain Neoplasms - metabolism
  • Data Interpretation, Statistical
  • Female
  • Glioma - metabolism
  • Humans
  • Indium Radioisotopes - blood
  • Indium Radioisotopes - pharmacokinetics
  • Male
  • Meningioma - metabolism
  • Meningioma - secondary
  • Middle Aged
  • Models, Biological
  • Organometallic Compounds - blood
  • Organometallic Compounds - pharmacokinetics
ispartof: Annals of nuclear medicine, 1998-12, Vol.12 (6), p.313-321
description: The kinetics of an indium-111 labeled bleomycin complex (111In-BLMC) after rapid intravenous injection in patients with brain tumors was quantified by using compartmental and non-compartmental models. The models were applied to data obtained from 10 glioma, one meningioma, and one adenocarcinoma brain metastasis patients. Blood and urine samples from all the patients and tumor samples from three patients were collected. The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool. The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h. The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1. The mean turnover time from the tumor was 4.5 +/- 2.7 min and from the depot 20 +/- 8 h. It is concluded that both compartmental and non-compartmental models are sufficient to describe the kinetics of indium-111 labeled bleomycin complex. The non-compartmental model is more practical and to some extent more efficient in describing the in vivo behaviors of 111In-BLMC than the compartmental model. The compartmental model used provides estimates of both extraction and excretion from the plasma and tumor.
language: eng
source:
identifier: ISSN: 0914-7187
fulltext: no_fulltext
issn:
  • 0914-7187
  • 1864-6433
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.6860718
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_proquest_miscellaneous_69168876
sourceformatXML
sourcesystemPC
sourcerecordid69168876
originalsourceidFETCH-LOGICAL-p112t-644547f0274a24f91d5acd4834a09bfdb01b1864be66aeed571577182716c94e0
addsrcrecordideNpVkEtLxDAUhYMo4zj6E4Ss3FWSNE1SdzL4GBxwo-uSNLcYyaM2qeK_t-JshAsHzvm43HOP0JoqwSvB6_oYrUlLeSWpkqfoLOd3QphqFFuhVdtKVgu1RuHJRSiuzzgNmFK6i5XXBjxYbDyk8N27iJcZdXEQS8ZfrrxhM-nFK3NIU77BfQqjnkpYcu3xZ77GMcXqvxuSBZ_P0cmgfYaLg27Q6_3dy_ax2j8_7La3-2qklJXlet5wORAmuWZ8aKltdG-5qrkmrRmsIdT81jQghAawjaSNXGoySUXfciAbdPW3d5zSxwy5dMHlHrzXEdKcO9FSoZQUC3h5AGcTwHbj5IKevrvDf8gPa39jNA
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid69168876
display
typearticle
titleKinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models
creatorRyynänen, P M ; Savolainen, S E ; Aronen, H J ; Korppi-Tommola, E T ; Huhmar, H M ; Kallio, M E ; Hiltunen, J V
creatorcontribRyynänen, P M ; Savolainen, S E ; Aronen, H J ; Korppi-Tommola, E T ; Huhmar, H M ; Kallio, M E ; Hiltunen, J V
descriptionThe kinetics of an indium-111 labeled bleomycin complex (111In-BLMC) after rapid intravenous injection in patients with brain tumors was quantified by using compartmental and non-compartmental models. The models were applied to data obtained from 10 glioma, one meningioma, and one adenocarcinoma brain metastasis patients. Blood and urine samples from all the patients and tumor samples from three patients were collected. The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool. The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h. The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1. The mean turnover time from the tumor was 4.5 +/- 2.7 min and from the depot 20 +/- 8 h. It is concluded that both compartmental and non-compartmental models are sufficient to describe the kinetics of indium-111 labeled bleomycin complex. The non-compartmental model is more practical and to some extent more efficient in describing the in vivo behaviors of 111In-BLMC than the compartmental model. The compartmental model used provides estimates of both extraction and excretion from the plasma and tumor.
identifier
0ISSN: 0914-7187
1EISSN: 1864-6433
2PMID: 9972368
languageeng
publisherJapan
subjectAdenocarcinoma - metabolism ; Adenocarcinoma - secondary ; Adult ; Aged ; Bleomycin - analogs & derivatives ; Bleomycin - blood ; Bleomycin - pharmacokinetics ; Brain Neoplasms - metabolism ; Data Interpretation, Statistical ; Female ; Glioma - metabolism ; Humans ; Indium Radioisotopes - blood ; Indium Radioisotopes - pharmacokinetics ; Male ; Meningioma - metabolism ; Meningioma - secondary ; Middle Aged ; Models, Biological ; Organometallic Compounds - blood ; Organometallic Compounds - pharmacokinetics
ispartofAnnals of nuclear medicine, 1998-12, Vol.12 (6), p.313-321
lds50peer_reviewed
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9972368$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Ryynänen, P M
1Savolainen, S E
2Aronen, H J
3Korppi-Tommola, E T
4Huhmar, H M
5Kallio, M E
6Hiltunen, J V
title
0Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models
1Annals of nuclear medicine
addtitleAnn Nucl Med
descriptionThe kinetics of an indium-111 labeled bleomycin complex (111In-BLMC) after rapid intravenous injection in patients with brain tumors was quantified by using compartmental and non-compartmental models. The models were applied to data obtained from 10 glioma, one meningioma, and one adenocarcinoma brain metastasis patients. Blood and urine samples from all the patients and tumor samples from three patients were collected. The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool. The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h. The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1. The mean turnover time from the tumor was 4.5 +/- 2.7 min and from the depot 20 +/- 8 h. It is concluded that both compartmental and non-compartmental models are sufficient to describe the kinetics of indium-111 labeled bleomycin complex. The non-compartmental model is more practical and to some extent more efficient in describing the in vivo behaviors of 111In-BLMC than the compartmental model. The compartmental model used provides estimates of both extraction and excretion from the plasma and tumor.
subject
0Adenocarcinoma - metabolism
1Adenocarcinoma - secondary
2Adult
3Aged
4Bleomycin - analogs & derivatives
5Bleomycin - blood
6Bleomycin - pharmacokinetics
7Brain Neoplasms - metabolism
8Data Interpretation, Statistical
9Female
10Glioma - metabolism
11Humans
12Indium Radioisotopes - blood
13Indium Radioisotopes - pharmacokinetics
14Male
15Meningioma - metabolism
16Meningioma - secondary
17Middle Aged
18Models, Biological
19Organometallic Compounds - blood
20Organometallic Compounds - pharmacokinetics
issn
00914-7187
11864-6433
fulltextfalse
rsrctypearticle
creationdate1998
recordtypearticle
recordideNpVkEtLxDAUhYMo4zj6E4Ss3FWSNE1SdzL4GBxwo-uSNLcYyaM2qeK_t-JshAsHzvm43HOP0JoqwSvB6_oYrUlLeSWpkqfoLOd3QphqFFuhVdtKVgu1RuHJRSiuzzgNmFK6i5XXBjxYbDyk8N27iJcZdXEQS8ZfrrxhM-nFK3NIU77BfQqjnkpYcu3xZ77GMcXqvxuSBZ_P0cmgfYaLg27Q6_3dy_ax2j8_7La3-2qklJXlet5wORAmuWZ8aKltdG-5qrkmrRmsIdT81jQghAawjaSNXGoySUXfciAbdPW3d5zSxwy5dMHlHrzXEdKcO9FSoZQUC3h5AGcTwHbj5IKevrvDf8gPa39jNA
startdate199812
enddate199812
creator
0Ryynänen, P M
1Savolainen, S E
2Aronen, H J
3Korppi-Tommola, E T
4Huhmar, H M
5Kallio, M E
6Hiltunen, J V
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
67X8
sort
creationdate199812
titleKinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models
authorRyynänen, P M ; Savolainen, S E ; Aronen, H J ; Korppi-Tommola, E T ; Huhmar, H M ; Kallio, M E ; Hiltunen, J V
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-p112t-644547f0274a24f91d5acd4834a09bfdb01b1864be66aeed571577182716c94e0
rsrctypearticles
prefilterarticles
languageeng
creationdate1998
topic
0Adenocarcinoma - metabolism
1Adenocarcinoma - secondary
2Adult
3Aged
4Bleomycin - analogs & derivatives
5Bleomycin - blood
6Bleomycin - pharmacokinetics
7Brain Neoplasms - metabolism
8Data Interpretation, Statistical
9Female
10Glioma - metabolism
11Humans
12Indium Radioisotopes - blood
13Indium Radioisotopes - pharmacokinetics
14Male
15Meningioma - metabolism
16Meningioma - secondary
17Middle Aged
18Models, Biological
19Organometallic Compounds - blood
20Organometallic Compounds - pharmacokinetics
toplevelpeer_reviewed
creatorcontrib
0Ryynänen, P M
1Savolainen, S E
2Aronen, H J
3Korppi-Tommola, E T
4Huhmar, H M
5Kallio, M E
6Hiltunen, J V
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6MEDLINE - Academic
jtitleAnnals of nuclear medicine
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Ryynänen, P M
1Savolainen, S E
2Aronen, H J
3Korppi-Tommola, E T
4Huhmar, H M
5Kallio, M E
6Hiltunen, J V
formatjournal
genrearticle
ristypeJOUR
atitleKinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models
jtitleAnnals of nuclear medicine
addtitleAnn Nucl Med
date1998-12
risdate1998
volume12
issue6
spage313
epage321
pages313-321
issn0914-7187
eissn1864-6433
abstractThe kinetics of an indium-111 labeled bleomycin complex (111In-BLMC) after rapid intravenous injection in patients with brain tumors was quantified by using compartmental and non-compartmental models. The models were applied to data obtained from 10 glioma, one meningioma, and one adenocarcinoma brain metastasis patients. Blood and urine samples from all the patients and tumor samples from three patients were collected. The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool. The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h. The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1. The mean turnover time from the tumor was 4.5 +/- 2.7 min and from the depot 20 +/- 8 h. It is concluded that both compartmental and non-compartmental models are sufficient to describe the kinetics of indium-111 labeled bleomycin complex. The non-compartmental model is more practical and to some extent more efficient in describing the in vivo behaviors of 111In-BLMC than the compartmental model. The compartmental model used provides estimates of both extraction and excretion from the plasma and tumor.
copJapan
pmid9972368